renovorx.com - שווי הפעילות העסקית RNXT

RenovoRx, Inc. (RNXT) is integrating catheters for local chemotherapy into oncological practice, generating long-term demand for high-cost consumables. The expansion of the center network is based on reducing the overall toxicity of therapy. However, a lack of profit due to clinical trials leaves the business dependent on investments. This chart on GURU.Markets confirms these data, pricing the company's value at 55.22.

Fundamental analysis begins with identifying assets whose value is justified by real operational data. This indicator aggregates market capitalization and debt obligations, subtracting cash to determine the total enterprise value for a business buyout. For RenovoRx, Inc. (RNXT), which has no sales and relies on patents, the calculation is based on speculative expectations. The lack of pricing power makes any sharp increase in the real volume of business value an unjustified risk of overpayment.